Category: Breaking news

Gennvax is advancing its strategic partnership with Kenya’s Ministry of Health, with the completion of a Memorandum of Understanding (MOU) currently in process. This collaboration focuses on enhancing vaccine access, supporting national health priorities, and moving toward self-sufficiency in vaccine production.

In addition to its health initiatives, Gennvax proudly sponsored Kenya’s Ministry of Health National Day on October 6th, supporting environmental sustainability and community engagement. In collaboration with Dr. Mary Muthoni Muriuki, Principal Secretary, State Department for Public Health and Professional Standards, Gennvax planted 200 trees and engaged local schools in campaigns to raise awareness about the environmental and societal benefits of tree planting.

This initiative reflects Gennvax’s broader commitment to:

• Integrating health and environmental responsibility by promoting green initiatives alongside public health programs.

• Community engagement and education, fostering awareness among students and local communities about climate change and sustainable practices.

• Partnership with government and educational institutions to support public health, environmental stewardship, and capacity-building initiatives.

• Long-term impact monitoring, including tracking the growth and survival of planted trees and linking these activities to local health and environmental outcomes.

Through these efforts, Gennvax continues to demonstrate its commitment to sustainable development, health equity, and community empowerment across Kenya and the broader African region.

Gennvax management held a high-level meeting with the Ministry of Science and Innovation of Uganda to discuss strategic collaboration in research and development.

The discussions focused on key partnership pillars, including:

• Upgrading laboratory infrastructure to support cutting-edge vaccine research.

• Conducting clinical trials for next-generation vaccines to ensure high readiness for outbreak response.

• Strengthening quality assurance through technical training and capacity-building initiatives

Gennvax management and team held a high-level meeting with the Ministry of Health of Uganda, including Hon. Margaret Muhanga Mugisa, Minister of State for Primary Health Care, and Hon. Anifa Kawooya Bangirana, Minister of State for Health in charge of General Duties.

During the meeting, both parties agreed to sign a Memorandum of Understanding (MOU) to formalize prospective collaboration. Gennvax also received an official letter of expression of support from the Ministry, marking a significant milestone in their partnership.

The collaboration aims to:

• Facilitate access to vaccines within Gennvax’s portfolio to address Uganda’s national health needs.

• Support technical training and knowledge exchange for Ugandan health professionals.

• Explore opportunities for local capacity building, including technology transfer and infrastructure development.

This initiative reflects Gennvax’s ongoing commitment to enhancing vaccine access, strengthening healthcare systems, and fostering regional collaboration across Africa.

Gennvax, Egypt’s pioneering vaccine manufacturing site, is dedicated to achieving self-sufficiency in core vaccines and contributing to Africa’s health security. In alignment with its vision to locally produce a significant share of the continent’s vaccine needs, Gennvax has embarked on its journey toward market access across Africa.

As a proud member of the Egyptian Vaccines Manufacturers Association (EVMA), Gennvax embraces its role in fostering regional collaboration and strengthening Africa’s biomanufacturing ecosystem. The company’s first destination on this strategic journey was Zimbabwe, where it received full support from Egypt’s Ministry of Foreign Affairs and the Egyptian Ambassador to Zimbabwe.

During a high-level meeting with Zimbabwe’s Ministry of Health and Child Care, Gennvax was honored to sign an Expression of Interest (EOI) with the Honorable Dr. Douglas Mombeshora, Minister of Health.

This agreement marks the beginning of a collaborative partnership aimed at:

• Facilitating access to vaccines within Gennvax’s portfolio to address Zimbabwe’s national health needs.

• Supporting technical training and knowledge exchange for Zimbabwean health professionals.

• Exploring opportunities for local capacity building, including potential technology transfer.

• Strengthening regulatory and quality assurance capabilities in vaccine evaluation and monitoring.

This milestone reflects Gennvax’s commitment to advancing vaccine equity, promoting regional self-reliance, and contributing to a healthier, more resilient Africa.

High-level meeting with Zimbabwe’s Ministry of Health and Child Care, Gennvax was honored to sign an Expression of Interest (EOI) with the Honorable Dr. Douglas Mombeshora, Minister of Health

As part of its commitment to strengthening regulatory partnerships across Africa, Gennvax held a high-level meeting with the Medicines Control Authority of Zimbabwe (MCAZ), represented by Dr. Zivanai Makoni, Head of the Evaluation and Registration Division.
During this strategic meeting, both parties agreed to initiate a pilot program that positions Egypt and Gennvax as the first collaborators to begin the vaccine registration submission process through the newly established MCAZ online platform.
Gennvax has officially received the first access link to commence the upload of its registration and evaluation files — a significant step toward accelerating the availability of quality-assured vaccines in the Zimbabwean market.
This collaboration reflects Gennvax’s ongoing efforts to enhance regulatory cooperation, streamline vaccine registration processes, and reinforce its role as a trusted African manufacturer committed to supporting health security and innovation across the continent.

“The Egyptian Ambassador to Zimbabwe / Hala Serag El Din and the entire embassy team extended their full support to our national project, reflecting the strong spirit of collaboration and shared commitment between Egypt and Zimbabwe toward advancing health and vaccine self-sufficiency across Africa,” said Gennvax representatives.

NAT Pharm Collaborates with Gennvax on Strategic Initiatives NatT Pharm, the leading procurement partner for Zimbabwean health authorities, along with its Managing Director, Newman B. Madzikwa, has formally agreed to collaborate with Gennvax on this strategic initiative. This partnership underscores a shared commitment to enhancing vaccine access, supporting local health systems, and strengthening regional healthcare capabilities.

Egyptian prime minister cabinet grants the golden license to “Gennvax Egypt” to establish and operate the largest scientific and regional R&D center and a facility to locally manufacture all kinds of vaccines and export them to the African continent from Egypt.

During today’s meeting, the Prime Minister approved the granting of the golden license to “Gennvax Egypt”, an Egyptian joint stock company. This license allows the company to establish and operate the first and largest pharmaceutical, vaccines, and medical serums factory. The factory will have a complete manufacturing cycle and will benefit from full technology transfer, ensuring it is designed to meet the highest global standards. Importantly, the necessary approvals from the International Health Organization for the export of WHO PQ vaccines will be obtained as part of the establishment process where a big part of the foreign direct investment will be allocated to maintain the WHO PQ accreditations and standard, it’s emphasized that the PQ should be an integral part of the facility establishment step by step. The project is done with investments amounting to $150 million and will be located on an area of approximately 49 thousand square meters in the new industrial economic zone of the Suez Canal.

Dr. Nibal Dahaba, shareholder & a member of the Board of Directors and General Manager of Gennecs holding company and Gennvax holding expressed her pride in the successful acquisition of the golden license for “Gennvax Egypt” to establish and operate a vaccine manufacturing plant. She stated that this significant milestone strongly aligns with the company’s strategy, which recognizes the vaccine industry as a vital sector with substantial contributions to the national economy. The establishment of the plant will enhance the company’s role in producing and innovating vaccines necessary for treating various diseases. Dr. Dahaba also mentioned that the project is anticipated to create between 500 and 700 job opportunities.
Mr. Adam Al-Daba, shareholder & CEO of Gennecs company and Gennvax Holding stated that the upcoming factory will become the largest of its kind in manufacturing all human vaccines, encompassing a complete production cycle that includes 19 different types of vaccines with full technology transfer. Notably, the factory will be equipped with advanced technology that positions it as a major hub for exporting medical vaccines to countries across Africa and globally. It has been built to meet the highest international standards, and to be eligible for “WHO” approvals, which will enable exports to all countries worldwide. Mr. Al- Daba further highlighted that a substantial portion of the project’s investments, approximately $60 million, has been allocated towards obtaining the necessary WHO PQ approvals for vaccine manufacturing, accreditation and export.

Dr. Dahaba provided insightful details on the impressive production capabilities of the new vaccine factory. According to her, the factory’s production capacity is set to reach an estimated 115 million doses per year on a single shift basis. However, this number can be easily doubled to 250 million doses, showcasing the factory’s potential for significant expansion. Moreover, the new facility will house a research & development center dedicated to the full R&D technologies and advanced biological research. Additionally, it will feature all the cold chain high tech supply chain that would cater the whole continent
. One of the features of the new factory is the strain bank customized to be specific to Africa, which will enable the facility to manufacture vaccines related to any African or regional pandemic promptly.

Dr. Dahaba also highlighted the significance of granting the golden license to Gennvax Egypt, emphasizing that it represents a crucial step towards the localization of an essential and strategic industry in Egypt. Golden license as per the presidential decree and strategy shall be granted to national & strategic projects with the below criteria:
​•​Contributes to increasing exports.
​•​Its financing depends on foreign funds transferred from abroad.
​•​The percentage of the local component of raw materials and production requirements in its products is no less than (50%).
​•​To be a national labor-intensive project.
​•​To be established in one of the areas in greatest need of development in accordance with decree No. 7 of 2020.
​•​Contributes to reducing the environmental impact, reducing heat and gas emissions, and improving the climate.
Aide in reducing imports.

This golden license is a major tool in attracting investors to work within Egypt’s borders, while also attracting foreign investments that can enhance the Egyptian economy and lead to an increase in the country’s domestic product, contributing to the desired economic development. Moreover, Gennvax project will be a new source of foreign currency and an export door, which will help to boost the Egyptian economy and promote the country’s international trade. This is expected to have a positive impact on the country’s economic growth and development, creating new opportunities for job creation and improving living standards.

Mr Adam also emphasized the company’s commitment to advancing the healthcare system in Egypt through its strategy to localize the industry and through the continuous medical education initiative Gennvax academy

قالت نيبال دهبة، الشريك المساهم والمدير التنفيذي لشركة جينيكس وجينفاكس القابضة، إن حصول شركة “جينفاكس إيجيبت” على الرخصة الذهبية لإقامة وتشغيل أول وأكبر مصنع للأدوية واللقاحات والأمصال الطبية لها في مصر يدعم بشكل كبير استراتيجية الشركة التي تعتبر صناعة اللقاحات من الصناعات المهمة ذات المردود الكبير على الاقتصاد الوطني.

وأضافت خلال بيان للشركة اليوم الأربعاء أن هذه الخطوة تعزز أيضا من دور الشركة في إنتاج وابتكار اللقاحات اللازمة لعلاج العديد من الأمراض، ومن المتوقع أن يوفر المشروع ما بين 500 إلى 700 فرصة عمل.

ووافق مجلس الوزراء، خلال اجتماعه اليوم، على منح شركة “جينفاكس إيجيبت”، شركة مساهمة مصرية، الرخصة الذهبية عن مشروع إقامة وتشغيل مصنع لتصنيع الأدوية واللقاحات والأمصال، وذلك على مساحة نحو 49 ألف م2، بالقطعة رقم 105، القطاع الصناعي الأول، المنطقة الاقتصادية لقناة السويس، العين السخنة، محافظة السويس، وتبلغ التكاليف الاستثمارية للمشروع نحو 150 مليون دولار.

وقال آدم الضبع، رئيس مجلس الادارة لشركة جينيكس وجينفاكس القابضة، إن المصنع سيكون الأكبر من نوعه في تصنيع اللقاحات الطبية من خلال دورة تصنيعية كاملة تنتج 19 نوعاً من اللقاحات الطبية، مشيرا إلى أن المصنع سيتم تشغيله لأول مرة من خلال تكنولوجيا تسمح له بأن يكون مركزاً رئيسياً لتصدير اللقاحات الطبية إلى كافة دول أفريقيا، والعالم.

وأضاف أن ذلك يأتي خاصة وأن المصنع تم بناؤه ليكون مؤهلاً للحصول على اعتمادات ” WHO” الذي يسمح بالتصدير إلى كافة دول العالم، لافتا إلى أنه تم تخصيص نحو 60 مليون دولار من استثمارات المشروع للحصول على اعتمادات منظمة الصحة العالمية الخاصة بتصنيع اللقاحات.

وأوضحت نيبال دهبة أن إنتاج المصنع من اللقاحات سيكون في حدود 115 مليون جرعة في العام خلال دورة عمل واحدة وخط إنتاج واحد، ويمكن مضاعفة الإنتاج إلى 250 مليون جرعة.

وأشارت إلى أن المصنع الجديد سيتضمن مركز أبحاث خاص بتصنيع اللقاحات، وتخليقها، فضلاً عن مخازن المبردة والثلاجات الخاصة باللقاحات، إضافة إلى بنك سلالات خاص بسلالات الأمراض الخاصة بأفريقيا، وهو ما سيمكن المصنع من توفير أية لقاحات تخص أي وباء أفريقي او إقليمي بدلاً من انتظار تصنيعها من شركات أخرى.

وأضافت: “يعد منح الرخصة الذهبية للشركة خطوة إيجابية نحو توطين هذه الصناعة الاستراتيجية المهمة في مصر”، لافتة إلى أنها تسهم في التيسير على المستثمرين وتحفيزهم للعمل داخل مصر، فضلاً عن دورها في جذب الاستثمارات الأجنبية، التي تنعش الاقتصاد المصري وتنعكس على زيادة الناتج المحلي وتحقيق التنمية الاقتصادية المرجوة.

وأيضا يعد هذا المشروع القومي مصدرا جديدا للعملة الصعبة وباب تصدير، وفقا لدهبة، التي أكدت أن الشركة في إطار استراتيجيتها لتوطين هذه الصناعة في مصر تعمل على إمداد المنظومة الطبية دائماً بكل ما هو جديد وحديث في هذا المجال.

وأشارت إلى أن الرخصة الذهبية تعد واحدة من أهم المحفزات الاقتصادية لجذب الاستثمارات للدولة، والتي وجه الرئيس عبد الفتاح السيسي بمنحها بهدف جذب الاستثمار والتيسير على المستثمرين، حيث يتم منحها للشركات التي تؤسس لإقامة مشروعات استراتيجية ولها بعد قومي يسهم في تحقيق التنمية المستدامة وفقا لخطة التنمية الاقتصادية للدولة.